Progress in Transcatheter Mitral Valve Replacement Transcatheter Mitral Valve Tendyne Device •...

Progress in Transcatheter Mitral

Valve Replacement SOLACI 2017

Eduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I.

Professor of Medicine & Surgery

Associate Dean for International Medicine

Program Director,

International Interventional Structural Heart Disease Fellowship

University of Miami Miller School of Medicine

Potential conflict of Interest

• Support for Educational Conference – Most Cardiovascular Corporations

• Active Sponsored Research Support – – Medtronic Other Conflicts:

1. Tendyne Medical Inc. - Co founder

2. Abbott Medical - Consultant

3. Intergene International LLC -Medical Advisory Board

4. Aegis Medical – Medical Advisory Board and stock holder

5. St. George Medical – consultant

6. Argo Medical – Investor/ Consultant

7. de Marchena Wellness - President

8. SwiftSynch – President

9. Vdyne – Advisory Board and investor

New Investigational Devices

******Not FDA or CE mark approved*******

4

Mirabel M, et al. Eur Heart J 2007;28:1358-1365

No surgery in 49%

Not all patients are good surgical candidates

396 patients in Europe with symptomatic severe MR (53% degenerative)

0

20

40

60

80

100

120

140

160Decision not tooperate

Decision tooperate

P<0.0001

63% 59% 67% 42%

15%

<50 50-60 60-70 70-80 >80

Stone ,G TVT2012

Prevalance of MR in US

de Marchena E, Badiye A, Robalino G, Junttila J, Atapattu S, Nakamura M,

De Canniere D, Salerno TJ Card Surg 2011;26:385-392

Carpentier’s functional classification.

Type I, normal leaflet motion;

Type II, increased leaflet motion (leaflet

prolapse);

Type IIIa restricted leaflet motion during

diastole and systole;

Type IIIb restricted leaflet motion predominantly

during systole.*

Mitral Valve Replacement

A Long Road

Anatomic Challenges

Pouch, A et al. Circulation

Mitral Valve Sizing

FMR/IMR Subjects

3D TEE

AP 33 - 40 mm

CC 40 - 44 mm

Topilsky, JAHA 2013; Khabbaz, ATS 2013; Kovalova, Echocardiography 2011

Mitral Annulus in the context of TMVI

Projected area

Leipsic J TVT 2014

Transcatheter Mitral Valve Implantation

(TMVI) Devices

Maisano EHJ 2015

CardiAQ Twelve Medtronic

Neovasc - Tiara

TMVR Candidates

Tendyne

Edwards Mitral Direct flow

Tendyne Valve

Tendyne Transcatheter Mitral Valve

Tendyne Device

• Tri-leaflet porcine pericardial valve

• Self-expanding nitinol double frame

• D-shaped outer frame, anterior cuff

• Large valve size matrix

• Single inner valve size

• Multiple outer frame sizes

• Large Effective Orifice Area (>3.0cm2)

• Transapical access, valve tethered to apex

• Adjustable tension provides valve stability

• Apical Pad assists in access closure

• Valve fully retrievable and repositionable

David WM Muller, MBBS, MD, TCT 2016

Animation Tendyne Valve

Site: Hospital Italiano;

Asuncion, Paraguay

Date: February & August, 2013

Team:

• Cardiac Surgery

• Georg Ludder

• Lucian Lozonski

• Adrian Ebner

• Santiago Gallo

• Interventional Cardiology

• Eduardo de Marchena

• Echocardiography

• Eduardo Alvarez

• James Berry

• Anesthesia

• Enrique Silva

• Technical assistant

• Dan Mans

• Bob Vidlund

• Zack Tegels

• Michael Evans

• Christian Marin y Kall

• Jeff Franco

Acute First in Man

Lutter G, Lozonshi Marin Y Kall C,… de Marchena E. J Am Coll Cardiol Intv. 2014;7(9):1077-1078

Tendyne Patient Number 1

• 57 y.o. man NYFC III from Myxomatous mitral valvular disease

• Echocardiographic findings • MR grade 4+ • Vena Contracta 8.0 mm • LA size 6.46 cm • Regurgitation fraction 35.4% • LV diastolic 51 mm; Systolic 35 mm • LVEF 59% • Carpentier class II with posterior leaflet prolapse

• STS mortality 7.1% and Mortality Morbidity 54.1%; Euroscore II - 8.8%. • Prolapse of posterior leaflet

22

Lutter G, Lozonshi Marin Y Kall C,… de Marchena E. J Am Coll Cardiol Intv. 2014;7(9):1077-1078

Baseline TEE patient 1

Lutter G, Lozonshi L,… de Marchena E. J Am Coll Cardiol Intv. 2014;7(9):1077-1078

Valve at annulus

Pre and Post Ventriculogram Patient 1

Transcardiac Echo of LV outflow post implantation Patient 1

3d short axis of valve

Lutter G, Lozonshi L,… de Marchena E. J Am Coll Cardiol Intv. 2014;7(9):1077-1078

Tendyne TMVI Trials

Compassionate Use (n=8)

• 3 sites

Global Feasibility Study (n=30)

• 8 sites, Australia, US and Norway

CE Mark Study/Expanded Feasibility Study (n=110)

• Up to 25 centers (10 US)

• Up to 40 US patients

Total experience to date:

• >50 cases, longest follow-up 2yrs

Tendyne TMVI Investigators

Global Feasibility Study (n=30)

• St Vincent’s Hospital, Sydney

• Abbott Northwestern, Minneapolis

• Prince Charles Hosp, Brisbane

• Baylor Heart and Vascular, Dallas

• Oslo University Hospital, Oslo

• Evanston Hospital, Chicago

• Cleveland Clinic, Cleveland

• Medstar Hospital, Washington DC

November 2014 – March 2016

Muller et al JACC In press

Tendyne GFS: Demographics (n=30)

Age at Baseline

Mean+SD 75.6+9.2 years

Range 55.1-91.4 years

Gender

Male 25 (83.3%)

Female 5 (16.7%)

NYHA Functional Class

II 14 (46.7%)

III 16 (53.3%)

IV 0 (0%)

STS Score (range) 7.3+5.7 (2-16 )


Tendyne GFS: Demographics

Co-morbidities N=30

Diabetes (all T2DM) 11 (36.7%)

Chronic lung disease/COPD 10 (33.3%)

Chronic kidney disease (eGFR<60) 17 (56.7%)

Prior CVA 2 (6.7%)

Prior thoracotomy

CABG 14 (46.7%)

Prior valve intervention/surgery 0 (0.0%)

Arrhythmia

Atrial fibrillation 17 (56.7%)

ICD/BiV PPM in situ 15 (50.0%)


Tendyne GFS: Patient Overview (n=30)

Baseline Mitral Valve pathology

Primary MR 3 (10%)

Secondary MR 23 (76.7%)

Mixed pathology 4 (13.3%)

Baseline LV function N=29

LVEF <30% 3 (10.3%)

LVEF 30-50% 14 (48.3%)

LVEF>50% 12 (41.4%)


GFS: Acute Outcomes

Outcome N=30

Death (all cause) 0 (0%)

CVA 0 (0%)

Major bleeding

Transfusion 3 (10%)

Device-related

Device embolization 0 (0%)

Cardiac perforation 0 (0%)

Paravalvular leak 1 (3.3%)

Device Retrieval

LVOT obstruction 1 (3.3%)

Did not properly seat - access issue 1 (3.3%)


Tendyne TMVI: D30 Outcomes

Outcome N=30

Death (all cause) 1 (3.3%)

Cardiac 0 (0%)

Non-cardiac 1 (3.3%)

CVA 0 (0%)

MV surgery 0 (0%)

Re-hospitalisation

Heart failure 4 (13.8%)

LVAD/transplant 0 (0%)

Other (ileus) 1 (3.3%)

Device-related

Hemolysis, transfusion 1 (3.3%)

Leaflet thrombosis 1 (3.3%)


0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Baseline 30 days

Grade IV

Grade III

Grade II

Grade I

None

MR severity post-TMVI (n=30)

3.3

6.9

93.1

90.0

6.7* *No device in situ (n=2)


Functional capacity post-TMVI (n=30)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Baseline Day 30

NYHA Class

Class IV

Class III

Class II

Class I

7.1

46.7

53.3

25.0

50.0

17.9

p=0.03


Tendyne TMVI: D30 QOL Outcome

0

10

20

30

40

50

60

70

Baseline 30days

KCCQ score

p=0.0018

50.2

64.6


Baseline Day 30

90.1

72.1

p=0.0012

0

20

40

60

80

100

120

140

160

180

LV End-Diastolic Volume Index (mls/m2)

LV Volume post-TMVI (n=30)


Baseline Day 30

48.4 43.1

p=0.18

0

10

20

30

40

50

60

70

80

90

100

1 2

LV End-Systolic Volume Index (mls/m2)

LV Volume post-TMVI (n=30)


Baseline Day 30

47.1 41.3

p=0.043

LV Function post-TMVI (n=30)

0

10

20

30

40

50

60

70

1 2

LV Ejection Fraction (%)


Day 30 CT: systole

Circumferential apposition of atrial skirt

Seated well at annulus/atrioventricular junction

Tether perpendicular to plane of annulus

The Trans-catheter Mitral Valve Replacement era has begun!

• Early phase mayor questions:

– Case selection

– New designs to minimize LVOT obstruction

– Proper planning and imaging for technique

– Thrombosis and long term anticoagulation

– Can Transapical approach be replaced by antegrade approaches

– Longevity of valve

Thank You

Progress in Transcatheter Mitral Valve Replacement Transcatheter Mitral Valve Tendyne Device •...

Documents

Transcript of Progress in Transcatheter Mitral Valve Replacement Transcatheter Mitral Valve Tendyne Device •...